Nichi-Iko Aims For ‘Commanding Presence’ In Japan Generics Via Eisai Alliance

Eisai has become the latest R&D-based pharma company in Japan to offload its non-innovative products as it seeks to maximize their sales and focus more on novelty and, by implication, the rewards this can bring under Japan’s evolving reimbursement pricing system.

businessman and businesswoman are exchanging document or contract
EISAI OFFLOADS JAPAN GENERICS BUSINESS TO NICHI-IKO

In what the companies said was an alliance seeking “increased profit for both companies,” Eisai Co. Ltd. is gradually to transfer full ownership of its Elmed Eisai generics business in Japan to Nichi-Iko Pharmaceutical Co. Ltd., one of the country’s largest generics concerns.

The move seeks to build on the assets and strengths of both firms in their respective sectors, and will involve...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Japan

More from Focus On Asia